CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the publication of key preclinical data from its ACE-011 program demonstrating that treatment using the ActRIIA receptor increases bone formation, bone mass and bone strength in mice. The paper titled,
